Oncolytics Biotech Number Of Shares Shorted vs. Total Debt
| ONCY Stock | USD 0.86 0.02 2.27% |
For Oncolytics Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncolytics Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncolytics Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncolytics Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncolytics Biotech over time as well as its relative position and ranking within its peers.
Oncolytics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Return On Assets (0.71) | Return On Equity (1.38) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncolytics Biotech Total Debt vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. Oncolytics Biotech is rated below average in number of shares shorted category among its peers. It is rated below average in total debt category among its peers making up about 0.16 of Total Debt per Number Of Shares Shorted. The ratio of Number Of Shares Shorted to Total Debt for Oncolytics Biotech is roughly 6.16 . Total Debt To Capitalization is likely to rise to 0.01 in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncolytics Biotech's earnings, one of the primary drivers of an investment's value.Oncolytics Total Debt vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Oncolytics Biotech |
| = | 2.6 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Oncolytics Biotech |
| = | 423 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Oncolytics Total Debt vs Competition
Oncolytics Biotech is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 835.69 Million. Oncolytics Biotech adds roughly 423,000 in total debt claiming only tiny portion of equities under Health Care industry.
Oncolytics Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncolytics Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncolytics Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Oncolytics Biotech's change in net profit over the period of time. It can combine multiple indicators of Oncolytics Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 544 K | 516.8 K | |
| Operating Income | -33.8 M | -32.1 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Income Tax Expense | 97 K | 92.2 K | |
| Net Loss | -32.4 M | -30.7 M | |
| Income Before Tax | -27.7 M | -29 M | |
| Total Other Income Expense Net | 6.1 M | 6.4 M | |
| Net Loss | -22.4 M | -21.2 M | |
| Net Interest Income | 1.2 M | 1.2 M | |
| Interest Income | 1.2 M | 1.2 M | |
| Change To Netincome | 801.5 K | 1.1 M | |
| Net Loss | (0.41) | (0.43) | |
| Income Quality | 1.03 | 0.71 | |
| Net Income Per E B T | 1.00 | 0.81 |
Oncolytics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncolytics Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncolytics Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncolytics Biotech's important profitability drivers and their relationship over time.
Use Oncolytics Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.Oncolytics Biotech Pair Trading
Oncolytics Biotech Pair Trading Analysis
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncolytics Biotech position
In addition to having Oncolytics Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.